# OnCo record nilotinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nilotinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nilotinib" ;
  schema:name "Nilotinib"@en ;
  schema:description "Nilotinib is a second-generation CML pill that produces deeper responses faster than imatinib, at the cost of cardiovascular and metabolic side effects."@en ;
  schema:url <https://onco.cc/drugs/nilotinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nilotinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q412327> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=nilotinib> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule BCR-ABL1 TKI (second generation)" ;
  schema:alternateName "Tasigna" ;
  onco:approval "US 2007: Ph+ CML, chronic or accelerated phase, resistant/intolerant to imatinib", "US 2010: Newly diagnosed Ph+ CML chronic phase", "EU 2007: Ph+ CML" ;
  onco:acceleratedApproval "US 2007-10-29: Chronic phase and accelerated phase Philadelphia chromosome positive CML in adults resistant or intolerant to prior therapy that included Gleevec (imatinib)", "US 2010-06-17: Newly diagnosed adults with with Philadelphia chromosome-positive CML in chronic phase" ;
  onco:acceleratedApprovalConfirmed "US 2011-01-14: Chronic phase and accelerated phase Philadelphia chromosome positive CML in adults resistant or intolerant to prior therapy that included Gleevec (imatinib)", "US 2015-01-27: Newly diagnosed adults with with Philadelphia chromosome-positive CML in chronic phase" ;
  onco:related <https://onco.cc/biomarkers/bcr-abl1-transcript/> ;
  onco:cancers <https://onco.cc/cancers/cml/>, <https://onco.cc/cancers/cml-chronic-phase/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/kit/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/nct04971226/>, <https://onco.cc/trials/nct05456191/> .